Bristol Myers Squibb (BMY) Com Stk USD 0.10 (CDI)
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.